Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306946767/en/

Contacts

Media and Investors
Jennifer Viera
617-744-3848
jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

Back to news